AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
+0.87 (2.01%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.11 - 44.69
52 week 16.49 - 44.69
Open 43.72
Vol / Avg. 952,418.00/460,933.00
Mkt cap 951.96M
P/E     -
Div/yield     -
EPS -0.50
Shares 22.09M
Beta 0.05
Inst. own 121%
Feb 4, 2015
Q4 2014 AMAG Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 20, 2014
AMAG Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London - Webcast
Oct 30, 2014
Q3 2014 AMAG Pharmaceuticals Inc Earnings Release
Oct 30, 2014
Q3 2014 AMAG Pharmaceuticals Inc Earnings Call - Webcast
Sep 29, 2014
AMAG Pharmaceuticals, Inc. to Acquire Lumara Health Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 5.72% -11.88%
Operating margin 16.84% -14.37%
EBITD margin - -9.22%
Return on average assets 1.30% -3.67%
Return on average equity 3.00% -5.56%
Employees 148 -
CDP Score - -


1100 Winter Street
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company markets Feraheme, an iron compound for the treatment of iron deficiency anemia in adult patients, and MuGard Mucoadhesive Oral Wound Rinse, an oral rinse for treating oral mucositis. Feraheme (ferumoxytol) Injection is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). MuGard is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces. It also operates the maternal health division through its subsidiary, Lumara Health Inc. Lumara Health is a marketer of Makena(R) (hydroxyprogesterone caproate injection), which is indicated to reduce the risk of preterm birth in women.

Officers and directors

Gino Santini Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
William K. Heiden President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frank E. Thomas Chief Operating Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 39
Bio & Compensation  - Reuters
Scott B. Townsend Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Age: 54
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development and Strategy
Bio & Compensation  - Reuters
Robert Blood Esq. Chief Compliance Officer, Vice President - Legal Affairs
Bio & Compensation  - Reuters
Judith Johnson M.D. Vice President - Pharmacovigilance & Pharmacoepidemiology
Bio & Compensation  - Reuters